Relapse of hepatitis C in a pegylated-interferon-α-2b plus ribavirin-treated sustained virological responder

Hepatology Research

Volumn 40, Issue 6, 2010, Pages 654-660

  Fujii, Hideki ^a   Itoh, Yoshito ^a   Ohnishi, Naoki ^a   Sakamoto, Masafumi ^a   Ohkawara, Tohru ^a   Sawa, Yoshihiko ^a   Nishida, Koichi ^a   Nishimura, Takeshi ^b   Yamaguchi, Kanji ^b   Yasui, Kohichiroh ^b   Minami, Masahito ^b   Okanoue, Takeshi ^c   Ohkawara, Yasuo ^a   Yoshikawa, Toshikazu ^b  

^a Aiseikai Yamashina Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Chronic hepatitis C; Genotype 2a; Phylogenetic analyses; Relapse; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; GLYCYRRHIZIC ACID; PEGINTERFERON ALPHA2B; RIBAVIRIN; STRONGER NEO MINOPHAGEN C; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CLINICAL FEATURE; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RELAPSE; VIRUS LOAD; VIRUS STRAIN;

EID: 77954373201     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00641.x     Document Type: Article

References (28)

1. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002, 36:S3-20.
2. Hayashi J, Kishihara Y, Yamaji K. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 1995, 90:794-9.
3. Ichida F, Tsuji T, Omata M. New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Internat Hepatol Comm 1996, 6:112-9.
4. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-93.
5. Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999, 37:2625-30.
6. Gargiulo F, De Francesco MA, Pinsi G. Determination of HCV genotype by direct sequence analysis of quantitative PCR products. J Med Virol 2003, 69:202-6.
7. Hayashi K, Katano Y, Honda T. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. J Med Virol 2009, 81:459-66.
8. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-9.
9. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-25.
10. Felsenstein J. Confidence limits on phylogenies: An approach using the bootstrap. Evolution 1985, 39:783-91.
11. Martell M, Esteban JI, Quer J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992, 66:3225-9.
12. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991, 88:3392-6.
13. Weiner AJ, Geysen HM, Christopherson C. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992, 89:3468-72.
14. Okamoto H, Kojima M, Okada S. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992, 190:894-9.
15. Lee WM, Polson JE, Carney DS, Sahin B, Gale M. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005, 192:1088-92.
16. Nakayama H, Sugai Y, Ikeya S, Inoue J, Nishizawa T, Okamoto H. Molecular investigation of interspousal transmission of hepatitis C virus in two Japanese patients who acquired acute hepatitis C after 40 or 42 years of marriage. J Med Virol 2005, 75:258-66.
17. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006, 43:1277-83.
18. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004, 78:5867-74.
19. Radkowski M, Gallegos-Orozco JF, Jablonska J. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005, 41:106-14.
20. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009, 49:665-75.
21. McHutchison JG, Poynard T, Esteban-Mur R. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002, 35:688-93.
22. Veldt BJ, Saracco G, Boyer N. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004, 53:1504-8.
23. Nakayama H, Ojima T, Kusano M, Endo K, Takahashi M, Sugai Y. Two cases of chronic hepatitis C with sustained virological response in whom serum HCV RNA reappeared two or twelve years after the end of IFN treatment. Kanzo 2006, 47:550-7. In Japanese
24. Enomoto N, Sakuma I, Asahina Y. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996, 334:77-81.
25. Akuta N, Suzuki F, Sezaki H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48:372-80.
26. Gale M, Blakely CM, Kwieciszewski B. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998, 18:5208-18.
27. Shiffman ML, Suter F, Bacon BR. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124-34.
28. Moucari R, Ripault MP, Oules V. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007, 46:596-604.